Takeda buys Abbott’s stake in TAP
Executive Summary
Japanese drug maker Takeda will be the sole owner of TAP Pharmaceutical Products after the firm finalizes a deal March 19 to buy Abbott's share of the 50/50 joint venture. When the transaction closes, TAP will be integrated into Takeda Pharmaceuticals North America and Takeda Global Research & Development Center, with the two reporting to a newly established Takeda America Holdings. Takeda says the deal will make the company a top 15 pharmaceutical company in the U.S. As part of the deal, Abbott and Takeda will evenly divide the value of the joint venture, with Abbott maintaining the rights to the prostate cancer drug Lupron (leuprolide acetate). Takeda gets rights to the only other TAP-marketed product - the heartburn and gastro-esophageal reflux medication Prevacid (lansoprazole)
You may also be interested in...
Takeda’s Millennium Buy Brings In Potential Cancer Blockbuster Velcade
Takeda made an aggressive move toward its goal of becoming a top three oncology company with the acquisition of Millennium for $8.8 billion
Health And Wellness Weekly Trademarks Review: 9 August
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Senate Cannabis Bill Could Torch US Hemp Market By Slashing THC Limit Below Farm Bill Level
Hemp Roundtable says Cannabis Administration and Opportunity Act’s limit of 0.001% THC per 100 g by dry weight for ingredients derived from cannabis to qualify as hemp “would impose a devastating setback to a thriving industry, and further limit opportunities for already struggling hemp farmers.”